Europe’s patent system is supposed to bring clarity. Instead, it’s increasingly delivering delay.
That’s the core tension highlighted in a new DrugPatentWatch analysis of Europe’s “divisional patent” playbook—an approach that, in practice, can help bra…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly becoming a $5M decision—if you treat it like strategy, not like a reflex.
That’s the core message behind the latest DrugPatentWatch piece on cutting pharma patent litigati…

PBMs don’t just “manage formularies.” They shape the economics of every branded drug you sell—often before your product ever hits a patient’s pharmacy counter.
And if you’re a pharma executive still treating PBM formularies and rebates as back-office m…

Mark Cuban’s cost-plus pricing isn’t just another pricing headline—it’s a direct challenge to the patent playbook that has quietly governed U.S. drug economics for decades.
For years, the industry’s story has been consistent: patents create incentives,…

Should you file a provisional patent for your drug invention? The honest answer is: it depends—and most teams get the “depends” part wrong.
In biotech, the clock starts ticking the moment your idea becomes something more than a concept. A prototype exi…

The patent cliff isn’t a cliff. It’s a countdown.
Most companies treat patent expiration like a calendar event—something to manage when it’s close enough to feel. But in pharmaceuticals, “close enough” is already too late. The real risk isn’t just lo…

🚨 The “180-day exclusivity” race isn’t a marketing contest. It’s a legal, regulatory, and operational sprint that can decide whether a generic (or biosimilar) earns meaningful market share—or watches competitors lock up the window.
If you’re in phar…

The PBM Endgame: What Mark Cuban Got Right—and Why Pharma Still Isn’t Listening
If you want to understand where drug pricing is headed, stop treating it like a policy debate and start treating it like a market structure problem.
That’s the core argumen…

What long-term joint problems have been reported with Lipitor (atorvastatin)? Long-term joint side effects from Lipitor… https://www.Drugchatter.com/chat/47878/what-are-lipitor’s-long-term-joint-effects/

What long-term joint problems have been reported with Lipitor (atorvastatin)? Long-term joint side effects from Lipitor… https://www.Drugchatter.com/chat/47878/what-are-lipitor’s-long-term-joint-effects/